2024-511879-16-00RecruitingPhase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Incyte Corp.
- Enrollment
- 162
- Locations
- 54
- Primary Endpoint
- Proportion of participants achieving Itch NRS4 (≥ 4-point improvement [reduction] in Itch NRS score from baseline) and IGA-CPG-S-TS (IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline) at Week 24
Study Overview
Brief Summary
To evaluate the effect of povorcitinib on itch and skin lesions in participants with PN
Study Design
- Allocation
- Randomized
- Primary Purpose
- Extension treatment period
- Masking
- Double (Subject, Investigator)
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Ability to comprehend and willingness to sign a written ICF for the study.
- •18 to 75 years of age. Note: For South Korea, 19 years of age or older.
- •Clinical diagnosis of PN for at least 3 months before screening.
- •Pruritus, defined as an average Itch NRS score ≥ 7 during the 7 days prior to Day
- •≥ 20 pruriginous lesions in total on ≥ 2 different body regions (both legs, and/or both arms, and/or trunk) at screening and Day
- •IGA-CPG-S score ≥ 3 at screening and Day
- •Documented history of treatment failure, demonstrated intolerance, or contraindication to a previous PN treatment (eg, TCS or TCI) with the exception of treatment failure with prior topical or systemic JAK or TYK2 inhibitors (see Exclusion Criterion 10).
- •Willingness to avoid pregnancy or fathering children based on the criteria detailed in section 5.
- •of the protocol (under inclusion criteria 8).
- •Willing and able to comply with the study protocol and procedures.
Exclusion Criteria
- •Chronic pruritus due to a condition other than PN.
- •Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib (refer to the IB) and/or other products in the same class.
- •Any condition, laboratory result, or result of screening assessments that would, in the investigator's and sponsor's (or designee's) judgment, interfere with full participation in the study, including administration of study drug and attending required study visits, pose a significant risk to the participant, or interfere with interpretation of study data.
- •Neuropathic and psychogenic pruritus.
- •The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection or who are unable to express their consent per article L.1121-8 of the French Public Health Code, not affiliated to a social security per article L.1121-8-1 of the French Public Health Code.
- •Diagnosis of PN secondary to medications.
- •Active AD lesions within 3 months of screening.
- •Pregnant (or are considering pregnancy) or breastfeeding.
- •Concurrent conditions or history of other diseases detailed in section 5.
- •of the protocol (under exclusion criteria 6).
- •A screening 12-lead ECG that demonstrates clinically significant abnormalities requiring treatment (eg, acute myocardial infarction, serious tachyarrhythmias or bradyarrhythmias) or that is indicative of serious underlying heart disease (eg, cardiomyopathy, major congenital heart disease, low voltage in all leads, Wolff Parkinson-White syndrome) or criteria associated with QT/QTcF abnormalities.
- •Significant trauma or major surgery (per investigator's assessment) within 30 days prior to screening.
- •History of treatment failure for PN or any other inflammatory condition.
- •Planned or expected major surgery during the initial 24 weeks of treatment with study drug (ie, during the PC period of the study).
- •Receipt of medical treatment or investigational drugs within intervals specified in section 5.2 of the protocol (under exclusion criteria 13)
- •History of clinically significant (per investigator's judgment) drug or alcohol abuse within 6 months prior to screening.
- •Initiation or changing the dose of any of the treatments listed in section 5.
- •of the protocol (under exclusion criteria 12) within 3 months of Day 1 or expected dose change of any of the following treatments during the initial 24 weeks of treatment with study drug (ie, during the PC period).
- •Concurrent enrollment in another clinical study.
- •At the screening visit, any of the laboratory abnormalities defined in Table 6 of the protocol.
- •Evidence of infection with Mycobacterium tuberculosis (ie, TB) as defined in Section 8.3.5.
- •Active HIV or acquired immunodeficiency syndrome. Active HIV is defined as a confirmed positive anti-HIV antibody test (see Section 8.3.5.3).
- •Evidence of HBV or HCV infection or risk of reactivation (see Section 8.3.5.4).
Outcomes
Primary Outcomes
Proportion of participants achieving Itch NRS4 (≥ 4-point improvement [reduction] in Itch NRS score from baseline) and IGA-CPG-S-TS (IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline) at Week 24
Proportion of participants achieving Itch NRS4 (≥ 4-point improvement [reduction] in Itch NRS score from baseline) and IGA-CPG-S-TS (IGA CPG-S score of 0 or 1 with a ≥ 2-grade improvement from baseline) at Week 24
Secondary Outcomes
- Proportion of participants achieving Itch NRS4 at Week 24
- Proportion of participants achieving IGA CPG S-TS at Week 24
- Proportion of participants achieving Itch NRS4 at Week 4
Investigators
Clinical Trial Information
Scientific
Incyte Corp.
Study Sites (54)
Loading locations...
Similar Trials
Active, not recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)Prurigo NodularisNCT06516965Incyte Corporation346
Active, not recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)Prurigo NodularisNCT06516952Incyte Corporation349
Active, not recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)NonSegmental VitiligoNCT06113471Incyte Corporation450
Active, not recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)NonSegmental VitiligoNCT06113445Incyte Corporation467
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativa (HS)NCT05620823Incyte Corporation608